Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343261 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma in the Treatment of COVID 19
A Phase 2 study of Coronavirus and COVID, sponsored by Trinity Health Of New England.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT04343261: Completed Phase 2 study of Coronavirus and COVID, sponsored by Trinity Health Of New England.
NCT04343261 is a Phase 2 study of Coronavirus and COVID that has completed, run by Trinity Health Of New England. The registered enrollment target is 48 participants, below the 1,403-participant average among 20 other Coronavirus trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04343261, a Phase 2 study of Coronavirus and COVID, has completed, sponsored by Trinity Health Of New England.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
Primary Outcome
Mortality within 28 days
Conditions Studied
Interventions
- BIOLOGICAL Convalescent Plasma
Study Locations (1)
Connecticut
- Trinity Health Of New England - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-04-10 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 2 |
What the finished NCT04343261 record still lists
NCT04343261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 1,403-participant average among 20 other Coronavirus trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Coronavirus appearing as the primary indexed condition, and to 1 intervention - of which Convalescent Plasma is the first listed.
NCT04343261 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04343261 about?
NCT04343261 is a clinical study titled "Convalescent Plasma in the Treatment of COVID 19". The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
What is the current status of trial NCT04343261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-04-10. Estimated completion is 2020-08-13.
What conditions does trial NCT04343261 study?
This clinical trial studies the following conditions: Coronavirus, COVID, Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2).
What interventions are being tested in trial NCT04343261?
The interventions under investigation include: Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04343261?
This trial is sponsored by Trinity Health Of New England, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04343261 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04343261's enrollment target sits among peer trials
48 20th of 20 higher than 1 of 20 other Coronavirus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronavirus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
COMPLETED · Phase 2
-
Convalescent Plasma to Stem Coronavirus (CSSC-001)
COMPLETED · Phase 2
-
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
COMPLETED · Phase 2
-
University of Utah COVID-19 Hydrochloroquine Trial
COMPLETED · Phase 2
-
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
RECRUITING
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI